ALZHEIMER’S DISEASE: A REVIEW

In fact, an estimated 25–29 percent of caregivers of persons age 50 or older (8.5–9.8 million caregivers) provide help to someone with a cognitive impairment, a memory problem, or

Effects of xanomeline, a selec- tive muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Bodick NC, Offen WW, Shannon HE,

This study investigated the effects of estrogen and selective estrogen receptor agonists on the regulation of mean arterial blood pressure and prostanoid function and on the roles

More frequent cognitive activity at baseline was associated with a higher level of cognitive function at baseline and, with this effect controlled, a less rapid rate of global

• Postmenopausal estrogen therapy reduces the risk of fracture, but due to risks associated with long-term use, is not recommended as a standard therapy for osteoporosisA.

Keywords: α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR); Carbon-11-labeled AMPAR allosteric modulator; Radiosynthesis; Positron emission

Food and Drug Administration (FDA) has approved two classes of drugs to treat cognitive symptoms of Alzheimer s disease.

The literature has demonstrated several risk factors for mortality in AD, including age, sex, baseline cognitive function, and functional disabilities [30, 31], which were also noted